Alibhlinftecunspadr Stock Fundamentals
| TWYA Stock | EUR 8.90 0.50 5.95% |
ALIBHLINFTECUNSPADR fundamentals help investors to digest information that contributes to ALIBHLINFTECUNSPADR's financial success or failures. It also enables traders to predict the movement of ALIBHLINFTECUNSPADR Stock. The fundamental analysis module provides a way to measure ALIBHLINFTECUNSPADR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ALIBHLINFTECUNSPADR stock.
ALIBHLINFTECUNSPADR |
ALIBHLINFTECUNSPADR Company Return On Equity Analysis
ALIBHLINFTECUNSPADR's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current ALIBHLINFTECUNSPADR Return On Equity | 0.0088 |
Most of ALIBHLINFTECUNSPADR's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ALIBHLINFTECUNSPADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, ALIBHLINFTECUNSPADR has a Return On Equity of 0.0088. This is 100.04% lower than that of the Healthcare sector and significantly higher than that of the Pharmaceutical Retailers industry. The return on equity for all Germany stocks is 102.84% lower than that of the firm.
ALIBHLINFTECUNSPADR Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ALIBHLINFTECUNSPADR's current stock value. Our valuation model uses many indicators to compare ALIBHLINFTECUNSPADR value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ALIBHLINFTECUNSPADR competition to find correlations between indicators driving ALIBHLINFTECUNSPADR's intrinsic value. More Info.ALIBHLINFTECUNSPADR is rated fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ALIBHLINFTECUNSPADR's earnings, one of the primary drivers of an investment's value.ALIBHLINFTECUNSPADR Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ALIBHLINFTECUNSPADR's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ALIBHLINFTECUNSPADR could also be used in its relative valuation, which is a method of valuing ALIBHLINFTECUNSPADR by comparing valuation metrics of similar companies.ALIBHLINFTECUNSPADR is currently under evaluation in return on equity category among its peers.
ALIBHLINFTECUNSPADR Fundamentals
| Return On Equity | 0.0088 | |||
| Return On Asset | -0.0168 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | (0.02) % | |||
| Shares Outstanding | 676.01 M | |||
| Revenue | 22.72 B | |||
| Gross Profit | 4.11 B | |||
| EBITDA | (505.28 M) | |||
| Net Income | 348.59 M | |||
| Cash And Equivalents | 11.64 B | |||
| Cash Per Share | 17.30 X | |||
| Total Debt | 37.74 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 4.18 X | |||
| Book Value Per Share | 22.12 X | |||
| Cash Flow From Operations | 1.01 B | |||
| Earnings Per Share | 0.02 X | |||
| Number Of Employees | 1.58 K | |||
| Beta | 1.01 | |||
| Market Capitalization | 10.11 B |
About ALIBHLINFTECUNSPADR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ALIBHLINFTECUNSPADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ALIBHLINFTECUNSPADR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ALIBHLINFTECUNSPADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, medical and healthcare services, and digital infrastructure businesses in the Peoples Republic of China. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. ALIB HL operates under Pharmaceutical Retailers classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1033 people.
Currently Active Assets on Macroaxis
Other Information on Investing in ALIBHLINFTECUNSPADR Stock
ALIBHLINFTECUNSPADR financial ratios help investors to determine whether ALIBHLINFTECUNSPADR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ALIBHLINFTECUNSPADR with respect to the benefits of owning ALIBHLINFTECUNSPADR security.